- Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
-
Lee SW, Choi J, Kim SU, Lim YS
- KMID: 2517623
- Clin Mol Hepatol.
- 2021 Jul;27(3):402-412.
- doi: 10.3350/cmh.2021.0179
Over the past several decades, entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have remained the first-line antiviral agents in several international guidelines. These two antiviral agents have shown similar short... -
- CITED
-
- Close
- SHARE
-
- Close
- Partial Virological Response after 2 Years of Entecavir Therapy Increases the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Virus-Associated Cirrhosis
-
Shin SK, Yim HJ, Kim JH, Lee CU, Yeon JE, Suh SJ, Jung YK, Kim YS, Kim JH, Kwon OS
- KMID: 2515847
- Gut Liver.
- 2021 May;15(3):430-439.
- doi: 10.5009/gnl20074
Background/Aims: The clinical significance of partial virological response (PVR) in patients undergoing antiviral therapy is not well known. This study investigated whether PVR after 2 years of entecavir (ETV) therapy... -
- CITED
-
- Close
- SHARE
-
- Close
- Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naïve Chronic Hepatitis B Patients in Korea
-
Choi H, Seo GH
- KMID: 2514900
- J Korean Med Sci.
- 2021 Apr;36(14):e89.
- doi: 10.3346/jkms.2021.36.e89
Background: The occurrence of hepatocellular carcinoma (HCC) is a major concern during antiviral therapy for chronic hepatitis B. There are conflicting opinions regarding the effects of entecavir (ETV) and tenofovir... -
- CITED
-
- Close
- SHARE
-
- Close
- Maintaining Antiviral Efficacy after Switching to Generic Entecavir 1 mg for Antiviral-resistant Chronic Hepatitis B
-
Ahn YE, Suh SJ, Kim TH, Jung YK, Yim HJ
- KMID: 2510772
- Korean J Gastroenterol.
- 2021 Jan;77(1):22-29.
- doi: 10.4166/kjg.2020.144
Background/Aims: Clinical equivalence of generic antiviral agents for chronic hepatitis B (CHB) has not been demonstrated, particularly in cases with previous antiviral resistance. Entecavir 1 mg is prescribed frequently as... -
- CITED
-
- Close
- SHARE
-
- Close
- Tenofovir does not induce renal dysfunction compared to entecavir in post-liver-transplant hepatitis B virus patients
-
Kim SJ, Rhu J, Lee SH, Kim JM, Choi GS, Kim K, Joh JW
- KMID: 2505493
- Ann Surg Treat Res.
- 2020 Sep;99(3):180-187.
- doi: 10.4174/astr.2020.99.3.180
Purpose: Tenofovir disoproxil fumarate is accepted as an effective and tolerable drug for treatment of HBV, similar to entecavir. However, there are some concerns about the nephrotoxicity of tenofovir. The... -
- CITED
-
- Close
- SHARE
-
- Close
- Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma
-
Mak LY, Ko KL, To WP, Wong DKH, Seto WK, Fung J, Yuen MF
- KMID: 2506442
- Gut Liver.
- 2020 Sep;14(5):665-668.
- doi: 10.5009/gnl19434
Serum hepatitis B core-related antigen (HBcrAg) was shown to predict the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients undergoing treatment. We investigated the longitudinal profile of... -
- CITED
-
- Close
- SHARE
-
- Close
- Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?
-
Jang BK
- KMID: 2504505
- Clin Mol Hepatol.
- 2020 Jul;26(3):312-314.
- doi: 10.3350/cmh.2020.0099
-
- CITED
-
- Close
- SHARE
-
- Close
- Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
-
Woo HY, Park JY, Bae SH, Kim CW, Jang JY, Tak WY, Kim DJ, Kim IH, Heo J, Ahn SH
- KMID: 2504510
- Clin Mol Hepatol.
- 2020 Jul;26(3):352-363.
- doi: 10.3350/cmh.2019.0044n
Background/Aims: Suboptimal responses to lamivudine or telbivudine plus adefovir (LAM/LdT+ADV) rescue therapy are common in patients with LAM-resistant hepatitis B virus (HBV) infections. We compared patients switched to entecavir plus... -
- CITED
-
- Close
- SHARE
-
- Close
- Influence of Besifovir Dipivoxil Maleate Combined with L-Carnitine on Hepatic Steatosis in Patients with Chronic Hepatitis B
-
Jung YW, Kim M, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim SU
- KMID: 2500207
- J Korean Med Sci.
- 2020 Apr;35(17):e104.
- doi: 10.3346/jkms.2020.35.e104
Background: Besifovir dipivoxil maleate (BSV) with L-carnitine is the first-line antiviral agent for chronic hepatitis B (CHB) infection. We investigated whether BSV combined with L-carnitine improves hepatic steatosis (HS). Methods: Treatment-naïve... -
- CITED
-
- Close
- SHARE
-
- Close
- Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis
-
Wang X, Liu X, Dang Z, Yu L, Jiang Y, Wang X, Yang Z
- KMID: 2508758
- Gut Liver.
- 2020 Mar;14(2):232-247.
- doi: 10.5009/gnl18546
Background/Aims: Studies have shown that nucleos(t)ide analogue (NA) treatment can reduce the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients, but it is unclear which NA is... -
- CITED
-
- Close
- SHARE
-
- Close
- Real World Experience of Telbivudine Versus Entecavir in Patients with Chronic Hepatitis B, Including Long-Term Outcomes after Treatment Modification
-
Choi JW, Kim SH, Seo JH, Cho YS, Won SY, Park BK, Jeon HH, Lee YK, Lee CK
- KMID: 2407861
- Yonsei Med J.
- 2018 May;59(3):383-388.
- doi: 10.3349/ymj.2018.59.3.383
PURPOSE: To estimate long-term outcomes after treatment modification in patients with chronic hepatitis B (CHB) treated with entecavir (ETV) and telbivudine (LdT). MATERIALS AND METHODS: The study enrolled 131 nucleos(t)ide analogue... -
- CITED
-
- Close
- SHARE
-
- Close
- A Multicenter Study of the Antiviral Efficacy of Entecavir Monotherapy Compared to Lamivudine Monotherapy in Children with Nucleos(t)ide-naïve Chronic Hepatitis B
-
Lee KJ, Choe BH, Choe JY, Kim JY, Jeong IS, Kim JW, Yang HR, Chang JY, Kim KM, Moon JS, Ko JS
- KMID: 2403318
- J Korean Med Sci.
- 2018 Feb;33(8):e63.
- doi: 10.3346/jkms.2018.33.e63
BACKGROUND: The aim of this study was to compare the long-term efficacy of entecavir (ETV) and lamivudine (LAM) therapy in children with chronic hepatitis B (CHB) who had not received... -
- CITED
-
- Close
- SHARE
-
- Close
- Large-scale surveillance study of the safety and effectiveness of entecavir in Korean patients with chronic hepatitis B
-
Kim CW, Kim CS, Kim HY, Lee CD, Yu K, Llamoso C, Lee HJ
- KMID: 2411513
- Korean J Intern Med.
- 2018 Jan;33(1):91-101.
- doi: 10.3904/kjim.2016.111
BACKGROUND/AIMS: Entecavir (ETV) is effective and safe antiviral agent against hepatitis B virus (HBV) in clinical and real-world setting but, most studies were performed in single institute or have limitation... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B
-
Lee KS, Kweon YO, Um SH, Kim BH, Lim YS, Paik SW, Heo J, Lee HJ, Kim DJ, Kim TH, Lee YS, Byun KS, Kim D, Lee MS, Yu K, Suh DJ
- KMID: 2406042
- Clin Mol Hepatol.
- 2017 Dec;23(4):331-339.
- doi: 10.3350/cmh.2016.0040
BACKGROUND/AIMS: Long-term data on antiviral therapy in Korean patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) are limited. This study evaluated the efficacy and safety of entecavir... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience
-
Kim HJ, Cho YK, Jeon WK, Kim BI
- KMID: 2406041
- Clin Mol Hepatol.
- 2017 Dec;23(4):323-330.
- doi: 10.3350/cmh.2017.0005
BACKGROUND/AIMS: Clinical characteristics of patients with chronic hepatitis B (CHB) who developed genotypic resistance to entecavir (ETV) were compared to those without resistance. METHODS: Two hundred fifty eight CHB patients who... -
- CITED
-
- Close
- SHARE
-
- Close
- Lamivudine: fading into the mists of time
-
Choi J, Lim YS
- KMID: 2406039
- Clin Mol Hepatol.
- 2017 Dec;23(4):314-315.
- doi: 10.3350/cmh.2017.0110
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Is it possible to predict the development of an entecavir resistance mutation in patients with chronic hepatitis B in clinical practice?
-
Nam JY, Lee JH
- KMID: 2406038
- Clin Mol Hepatol.
- 2017 Dec;23(4):311-313.
- doi: 10.3350/cmh.2017.0069
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis
-
Park J, Jung KS, Lee HW, Kim BK, Kim SU, Kim DY, Ahn SH, Han KH, Park JY
- KMID: 2395388
- Gut Liver.
- 2017 Nov;11(6):828-834.
- doi: 10.5009/gnl16484
BACKGROUND/AIMS: The renal effects of nucleos(t)ide analogs in patients with chronic hepatitis B are controversial. We aimed to compare the impact of entecavir (ETV) and tenofovir (TDF) on renal function... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir
-
Jeon HJ, Jung SW, Park NH, Yang Y, Noh JH, Ahn JS, Kim HR, Lee JH, Shin JW
- KMID: 2400670
- Clin Mol Hepatol.
- 2017 Sep;23(3):230-238.
- doi: 10.3350/cmh.2017.0003
BACKGROUND/AIMS: Tenofovir disoproxil fumarate (TDF) monotherapy for 48 weeks provided a virological response comparable to that of TDF and entecavir (ETV) combination therapy in patients infected with ETV-resistant hepatitis B... -
- CITED
-
- Close
- SHARE
-
- Close
- Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus?
-
Lee YB, Lee JH
- KMID: 2400667
- Clin Mol Hepatol.
- 2017 Sep;23(3):219-221.
- doi: 10.3350/cmh.2017.0045
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
